Michele V. McNeill, Pharm.D.
Joined the amfAR board in December 1996. Expertise in management of process for drug testing and approval. Was instrumental in establishing the Paul Corser AIDS Research Opportunity Fund, pledging $2 for every dollar, up to $100,000, contributed by amfAR donors. The Opportunity Fund supports projects that fall outside amfAR’s targeted research initiatives or regular grant cycles.
Dr. McNeill is founder and former chief executive officer of Kern McNeill International (KMI), a contract research organization providing clinical drug development services to research-based pharmaceutical manufacturers. At KMI, she pioneered work to provide access to investigational drugs for serious, life-threatening illnesses, such as AIDS and cancer. More than 80,000 patients received treatment from programs managed by KMI, prior to its acquisition several years ago by United Healthcare, Inc.
Earlier, Dr. McNeill practiced clinical pharmacy at Thomas Jefferson University Hospital in Philadelphia and at Erie County Medical Center in Buffalo. She launched her career in the pharmaceutical industry at Warner Lambert and went on to hold key management positions at Hoffmann-La Roche and Ciba-Geigy (now Novartis). Currently, Dr. McNeill serves on the Therapeutic and Research Working Group in the Office of AIDS Research at the National Institutes of Health.
She and her husband, Doug, live in Sarasota, FL